The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1521
May 22, 2017
View Complete Issue         Table of Contents 2019 
Oxymetazoline Cream (Rhofade) for Rosacea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oxymetazoline Cream (Rhofade) for Rosacea
May 22, 2017 (Issue: 1521)
The FDA has approved the selective alpha1A-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent facial erythema of rosacea in adults. Brimonidine, a selective alpha2-adrenergic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Oxymetazoline Cream (Rhofade) for Rosacea
Article code: 1521c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.